Thanks to its unique technology platform there is a hidden stock poised to profit from the recent takeover of diabetes drugmaker Amylin. Find out why Alkermes is uniquely positioned to reap rewards and why investors should take notice of its recent success in this video.
Alkermes isn't the only company with technology revolutionizing the way we live. For instance, the amount of data we store every year is growing by a mindboggling 60% annually! To makes sense of this trend and pick out a winner, The Motley Fool has compiled a new report called The Only Stock You Need To Profit From the NEW Technology Revolution. The report highlights a company that has gained 300% since first recommended by Fool analysts but still has plenty of room left to run. Thousands have requested access to this special free report, and now you can access it today at no cost. To get instant access to the names of this company transforming the IT industry, click here -- it's free.
The article The Hidden Winner of This Takeover originally appeared on Fool.com.
David Williamson owns shares of Johnson & Johnson, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.